Editorial
|
|
|
|
|
First, do no harm
|
|
|
|
New Products
|
|
|
|
|
A last-line treatment option for multiple myeloma
|
|
|
|
|
|
|
|
|
|
|
|
The standard intravenous treatment for severe attacks of malaria
|
|
|
|
|
|
|
|
|
|
An unjustified irritant effect in discrete actinic keratosis
|
|
|
|
|
|
|
|
|
|
The third HIV integrase inhibitor: one more option
|
|
|
|
Adverse Effects
|
|
|
|
|
No justification to keep it on the market
|
|
|
|
|
|
|
|
|
|
|
|
Apparently common with this class of drugs
|
|
|
|
|
|
|
|
|
|
Informing patients on interferon
|
|
|
|
|
|
|
|
|
|
|
|
Direct sunlight should be avoided
|
|
|
|
Reviews
|
|
|
|
|
First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects
|
|
|
|
|
|
|
|
|
|
Favourable harm-benefit balance
|
|
|
|
Outlook
|
|
|
|
|
A central part of decision-making
|
|
|
|
|
|
|
|
|
|